Advanced Therapies Platform for Cell, Gene and Tissue Engineering

Who we are

The Advanced Therapies Platform at Hospital Sant Joan de Déu is a GMP-certified facility authorised to manufacture CAR-T cell therapies for both paediatric and adult patients. The 1,280 m² facility includes four clean rooms dedicated to the production of cell therapies, gene therapies and tissue-engineered products, supported by state-of-the-art R&D, cryopreservation and storage infrastructures.

The platform supports the full translational pathway from preclinical development to GMP manufacturing and clinical implementation, operating according to the highest European regulatory standards. It actively collaborates with academic institutions, hospitals and industry partners and is part of multiple national and European advanced therapy networks.

We are particularly interested in Horizon Europe projects addressing:

• Advanced Therapy Medicinal Products (ATMPs).

• Cell and gene therapy development.

• Bio-printing and regenerative medicine.

• Personalised and precision medicine approaches.

• AI-driven manufacturing optimisation and quality control.

• Novel biomarkers for patient stratification and treatment monitoring.

• Advanced diagnostics supporting therapy selection and monitoring.

• Innovative clinical translation and scale-up pathways for advanced therapies.

What we bring to a consortium

• GMP-certified manufacturing facilities for CAR-T, cell, gene and tissue-engineered therapies.

• Expertise in development, scale-up and clinical translation of ATMPs.

• Access to specialised paediatric patient populations and clinical trial environments.

• Experience in early-phase and investigator-initiated clinical studies.

• Infrastructure for translational research from laboratory to bedside.

• Quality, regulatory and GMP compliance expertise.

• Cryopreservation, storage and logistics capabilities.

• Collaboration experience with academia, hospitals, SMEs and pharmaceutical companies.

• Participation in national and European advanced therapy networks.

• Clinical validation capabilities for innovative regenerative medicine technologies.